Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
BerGenBio Announces the Establishment of Oncology Scientific Advisory Board PR Newswire BERGEN, Norway, Feb. 2, 2023 - Distinguished global...
BerGenBio reports third quarter 2022 financial results and provides business update PR Newswire BERGEN, Norway, Nov. 15, 2022 - Randomized first...
BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS PR Newswire BERGEN, Norway, Oct. 25, 2022 BERGEN, Norway, Oct. 25...
BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11...
BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS PR Newswire BERGEN...
BerGenBio reports second quarter and half year 2022 financial results and provides business update PR Newswire BERGEN, Norway, Aug. 23, 2022...
BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19 PR Newswire BERGEN, Norway, May 4, 2022 BerGenBio to focus on two...
BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관